Treatments which heighten the immune response can inhibit tumor growth in susceptible hosts. For example, BCG administered with tumor cells or injected into established intradermal tumors (1, 2) resulted in specific, systemic tumor immunity in guinea pigs. These procedures, however, depended upon direct contact of BCG and tumor cells; contralateral challenges were less effective (3). Another ap...

Dendritic cells (DC) play a major role during the priming phase of anti-tumor immunization, as they are required for an efficient tumor-associated antigens presentation. At least one dendritic cell-based therapy has already been successfully approved by regulators clinical application in prostate cancer patients. Moreover, DC development is dependent on granulocyte macrophage colony stimulating...

Abstract The IL-1 family receptor antagonist IL-38 suppresses auto-inflammatory reactions in murine disease models. Given the connection between auto-immunity and anti-tumor immunity, we wondered if targeting would affect latter. transgenic PyMT mammary carcinoma model was employed to target genetically or with a neutralizing antibody. IL-38-deficient (KO) mice had markedly delayed tumor growth...

Abstract Intense pulsed electric fields (PEF) are increasingly employed for tumor ablation, including inoperable tumors, bleeding metastases, and tumors unresponsive to alternative treatments. PEF disrupt the membrane barrier of cells leading irreversible changes in homeostasis cell death. Using different models, we found that treatment with nanosecond duration (nsPEF) enhance host antitumor im...